Translate Bio Announces Publication of Preclinical Data Demonstrating Efficacy of Systemic mRNA Delivery in Fabry Disease Model in the Journal Molecular Therapy
Telesis Bio, Inc. (TBIO)
US:NASDAQ Investor Relations:
businesswire.com/news/home/20170630005160/en/precipio-diagnostics-transgenomic-complete-merger
Company Research
Source: GlobeNewswire
LEXINGTON, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the publication of preclinical results demonstrating efficacy in a mouse model of Fabry disease using a lipid nanoparticle (LNP) formulation for systemic delivery of mRNA derived from the Company’s mRNA therapeutic (MRT) platform. Fabry disease is a rare inherited disorder caused by a deficiency of a-galactosidase A. The disease is progressive, destructive and potentially life-threatening. The paper, published in the journal Molecular Therapy and titled Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy, reported the sustained expression of human a-galactosidase (GLA) protein via LNP-formulated mRNA in mice and non-human primates. The
Show less
Read more
Impact Snapshot
Event Time:
TBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBIO alerts
High impacting Telesis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
TBIO
News
- Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership [Yahoo! Finance]Yahoo! Finance
- Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadershipGlobeNewswire
- Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire
- Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial ResultsGlobeNewswire
TBIO
Earnings
- 3/28/24 - Miss
TBIO
Sec Filings
- 4/19/24 - Form 4
- 4/19/24 - Form DEF
- 4/18/24 - Form 8-K
- TBIO's page on the SEC website